source
- Kyverna Therapeutics aims to file first CAR-T cell therapy for autoimmune diseaseKyverna Therapeutics is preparing what could become the first regulatory filing for a CAR-T cell therapy targeting an autoimmune condition. The company has been developing its miv-cel construct in…
- Kolon’s cell-based gene therapy misses key endpoints in phase 3 osteoarthritis trialKolon TissueGene reported that its phase 3 study of TG‑C, a cell‑based gene therapy for knee osteoarthritis, failed to meet its co‑primary endpoints. Patients receiving the therapy showed no statis…